FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247246369> ?p ?o ?g. }

• W2247246369 endingPage "v1" @default.
• W2247246369 startingPage "v1" @default.
• W2247246369 abstract "ABSTRACT Aim: Next generation sequencing studies have identified defects in DNA repair machinery in 20-40% of sporadic castration resistant prostate cancer (CRPC) patients (pt). We hypothesized that single agent PARP inhibition would have antitumour activity based on synthetic lethality in CRPC. Methods: An investigator initiated adaptive multi-part Phase II trial (TOPARP; CR-UK/11/029) was pursued to assess olaparib antitumour activity and identify predictive biomarkers for response in CRPC. Part A is a 2-stage open labeled multi-centre study [po = 0.05; p1= 0.20; a = 0.02; b = 0.10; 30/45 pt]. Olaparib dosing was with 400mg tablets BID continuously. The primary endpoint was response, defined as a confirmed radiological response (RECIST 1.1), confirmed PSA decline ≥50% and/or confirmed circulating tumour cells (CTC) count fall from ≥5 to Results: Preliminary results are available for the first stage after 30 pt have been evaluated for the primary endpoint. Prior lines of treatment include docetaxel (n = 30, 100%), cabazitaxel (17, 57%), abiraterone (29, 97%) and enzalutamide (5, 17%). CRPC biopsies for biomarker studies were acquired from bone marrow (17), nodal/soft tissue disease (10) or visceral metastasis (3). The most common grade > 3 adverse events (AE) were anaemia (6, 20%) and fatigue (3, 10%). Olaparib was well tolerated; 6 (20%) pt required a dose reduction, with no permanent discontinuations due to drug-related AEs. Response rate was 33% (10/30 pt, Table 1). Median time on treatment for responding pt was 6.9 months (range 2.8m-14.4m). Somatic cell exome and transcriptome analyses have identified loss of function of genes involved in DNA repair including BRCA2 and ATM among the responding patients. Response assessment (PSA, CTC count and radiological response) for the patients who achieved a response per protocol definition (10 out of 30, response rate 33%) Responder patient ID Maximum PSA decline from baseline Measurable disease at baseline Best RECIST response (if measurable disease) Confirmed CTC conversion Baseline CTC count (cells/7.5ml blood) Maximum CTC decline from baseline Time on treatment (weeks) (+: on-going) 1 No decline Yes PD Yes 6 83.3% 12 2 47.3% No Yes 38 94.7% 62 3 94.6% Yes PR Yes 8 100% 24 4 58.7% Yes SD Yes 22 100% 36 + 5 80.1% No Unconfirmed 87 100% 42 + 6 79.9% Yes PR Yes 18 100% 36 7 29.3% Yes SD Yes 105 97.1% 17 8 82.6% No Yes 102 100% 39 9 51.2% No Yes 24 100% 32 + 10 No decline Yes SD Yes 38 100% 12 + Conclusions: Olaparib has antitumour activity in sporadic mCRPC with DNA repair defects; multiple durable responses have led to continuation to the next stage of this trial, which is nearing completion. Disclosure: A.G. Omlin: has served as advisor for Astra-Zeneca; J.S. de Bono: has served as paid advisor for Astra-Zeneca. All other authors have declared no conflicts of interest." @default.
• W2247246369 created "2016-06-24" @default.
• W2247246369 creator A5000156180 @default.
• W2247246369 creator A5003311852 @default.
• W2247246369 creator A5005619823 @default.
• W2247246369 creator A5014912122 @default.
• W2247246369 creator A5023060192 @default.
• W2247246369 creator A5033415518 @default.
• W2247246369 creator A5037380661 @default.
• W2247246369 creator A5041581270 @default.
• W2247246369 creator A5041969793 @default.
• W2247246369 creator A5056339622 @default.
• W2247246369 creator A5059792318 @default.
• W2247246369 creator A5062820099 @default.
• W2247246369 creator A5064026461 @default.
• W2247246369 creator A5068910261 @default.
• W2247246369 creator A5072378199 @default.
• W2247246369 creator A5077292948 @default.
• W2247246369 creator A5078001213 @default.
• W2247246369 creator A5080919044 @default.
• W2247246369 creator A5082993213 @default.
• W2247246369 creator A5085732690 @default.
• W2247246369 date "2014-09-01" @default.
• W2247246369 modified "2023-09-27" @default.
• W2247246369 title "Antitumour Activity of the Parp Inhibitor Olaparib in Unselected Sporadic Castration-Resistant Prostate Cancer (Crpc) in the Toparp Trial" @default.
• W2247246369 doi "https://doi.org/10.1093/annonc/mdu438.20" @default.
• W2247246369 hasPublicationYear "2014" @default.
• W2247246369 type Work @default.
• W2247246369 sameAs 2247246369 @default.
• W2247246369 citedByCount "11" @default.
• W2247246369 countsByYear W22472463692015 @default.
• W2247246369 countsByYear W22472463692016 @default.
• W2247246369 countsByYear W22472463692018 @default.
• W2247246369 countsByYear W22472463692019 @default.
• W2247246369 countsByYear W22472463692020 @default.
• W2247246369 crossrefType "journal-article" @default.
• W2247246369 hasAuthorship W2247246369A5000156180 @default.
• W2247246369 hasAuthorship W2247246369A5003311852 @default.
• W2247246369 hasAuthorship W2247246369A5005619823 @default.
• W2247246369 hasAuthorship W2247246369A5014912122 @default.
• W2247246369 hasAuthorship W2247246369A5023060192 @default.
• W2247246369 hasAuthorship W2247246369A5033415518 @default.
• W2247246369 hasAuthorship W2247246369A5037380661 @default.
• W2247246369 hasAuthorship W2247246369A5041581270 @default.
• W2247246369 hasAuthorship W2247246369A5041969793 @default.
• W2247246369 hasAuthorship W2247246369A5056339622 @default.
• W2247246369 hasAuthorship W2247246369A5059792318 @default.
• W2247246369 hasAuthorship W2247246369A5062820099 @default.
• W2247246369 hasAuthorship W2247246369A5064026461 @default.
• W2247246369 hasAuthorship W2247246369A5068910261 @default.
• W2247246369 hasAuthorship W2247246369A5072378199 @default.
• W2247246369 hasAuthorship W2247246369A5077292948 @default.
• W2247246369 hasAuthorship W2247246369A5078001213 @default.
• W2247246369 hasAuthorship W2247246369A5080919044 @default.
• W2247246369 hasAuthorship W2247246369A5082993213 @default.
• W2247246369 hasAuthorship W2247246369A5085732690 @default.
• W2247246369 hasBestOaLocation W22472463691 @default.
• W2247246369 hasConcept C104317684 @default.
• W2247246369 hasConcept C121608353 @default.
• W2247246369 hasConcept C126322002 @default.
• W2247246369 hasConcept C143998085 @default.
• W2247246369 hasConcept C182979987 @default.
• W2247246369 hasConcept C2779138821 @default.
• W2247246369 hasConcept C2779962180 @default.
• W2247246369 hasConcept C2780192828 @default.
• W2247246369 hasConcept C502942594 @default.
• W2247246369 hasConcept C54355233 @default.
• W2247246369 hasConcept C71924100 @default.
• W2247246369 hasConcept C82381507 @default.
• W2247246369 hasConcept C86803240 @default.
• W2247246369 hasConceptScore W2247246369C104317684 @default.
• W2247246369 hasConceptScore W2247246369C121608353 @default.
• W2247246369 hasConceptScore W2247246369C126322002 @default.
• W2247246369 hasConceptScore W2247246369C143998085 @default.
• W2247246369 hasConceptScore W2247246369C182979987 @default.
• W2247246369 hasConceptScore W2247246369C2779138821 @default.
• W2247246369 hasConceptScore W2247246369C2779962180 @default.
• W2247246369 hasConceptScore W2247246369C2780192828 @default.
• W2247246369 hasConceptScore W2247246369C502942594 @default.
• W2247246369 hasConceptScore W2247246369C54355233 @default.
• W2247246369 hasConceptScore W2247246369C71924100 @default.
• W2247246369 hasConceptScore W2247246369C82381507 @default.
• W2247246369 hasConceptScore W2247246369C86803240 @default.
• W2247246369 hasLocation W22472463691 @default.
• W2247246369 hasOpenAccess W2247246369 @default.
• W2247246369 hasPrimaryLocation W22472463691 @default.
• W2247246369 hasRelatedWork W2797380296 @default.
• W2247246369 hasRelatedWork W3023457002 @default.
• W2247246369 hasRelatedWork W3044648685 @default.
• W2247246369 hasRelatedWork W3081135235 @default.
• W2247246369 hasRelatedWork W3208352425 @default.
• W2247246369 hasRelatedWork W4200121834 @default.
• W2247246369 hasRelatedWork W4224114820 @default.
• W2247246369 hasRelatedWork W4250426713 @default.
• W2247246369 hasRelatedWork W4283513602 @default.
• W2247246369 hasRelatedWork W4297477309 @default.
• W2247246369 hasVolume "25" @default.
• W2247246369 isParatext "false" @default.

• next